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Determination of accurate anti-A/-B titers is important for 
treatment selection in ABO-incompatible stem cell and solid-
organ transplants. The standard method for ABO antibody 
titration is the conventional tube test (CTT). Dithiothreitol (DTT) 
is commonly used to inactivate the IgM antibody component. The 
aim of this study was to compare six different methods for ABO 
antibody titration and to observe the effectiveness of DTT on 
antibody estimation. A total of 90 healthy voluntary blood donors 
were enrolled in this study, including 30 each for blood groups A, 
B, and O. Antibody titrations were performed and tested using the 
CTT-immediate spin (IS), CTT-antihuman globulin (AHG) with 
and without DTT, column agglutination technology (CAT)-IS, and 
CAT-AHG with and without DTT methods. Bead-CAT was used, 
and the positive cutoff value was set to 1+ for each method to 
determine the endpoint of the titer. The median values of anti-A/-B 
titers by IS were found to be higher than those values by AHG 
in CTT and CAT among group B and A individuals, whereas no 
statistically significant differences were observed in values from 
group O individuals for IS and AHG anti-A/-B titers, estimated 
by each method. Although there was positive correlation between 
the anti-A/-B titer results obtained using the CTT and CAT in all 
blood groups, testing using AHG showed poor agreement with 
and without DTT pretreatment (kappa value of 0.11 and 0.20, 
respectively). Moderate agreement was observed between CTT-
IS and CAT-IS (kappa value of 0.46). Median anti-A/-B AHG 
titers were reduced by the use of DTT in all blood group samples. 
Significant differences in the interpretability of anti-A/-B titers 
were observed among different methods. A uniform approach 
for selecting the method for ABO antibody titration is highly 
recommended, and DTT pretreatment of plasma to neutralize 
IgM activity should be considered to obtain precise values of IgG 
anti-A/-B titers. Immunohematology 2021;37:25–32.
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ABO blood group antigens are called histo-antigens 
because they are known to be expressed not only on red 
blood cells (RBCs) but also on almost all other organs in 
the human body.1 ABO antibodies are naturally occurring, 
characterized as causing hemolytic transfusion reactions, 
hemolytic disease of the fetus and newborn, and antibody-
mediated rejection of solid-organ transplants. In ABO-
incompatible stem cell transplants, anti-A/-B titer levels 
correlate with the risk of immediate or delayed hemolysis, 
delaying the engrafting of RBCs.2 Both immunoglobulin 
(Ig)G and IgM anti-A/-B show hemagglutination with RBCs 
at or below room temperature and can activate complement 
at 37°C.3 Determining accurate anti-A/-B titers is beneficial 
for treatment selection, since patients with high anti-A/-B 
titer undergoing ABO-incompatible transplantation may 
be treated with anti-CD20 monoclonal antibody infusion, 
double-filtration plasmapheresis, or plasma exchange to 
reduce ABO antibody levels before the transplantation.4 The 
most common and recommended method for ABO antibody 
titration is the conventional tube test (CTT). Testing by the 
CTT-immediate spin (IS) using normal-ionic-strength saline 
is commonly used for determination of IgM antibody, and 
testing by the CTT-antihuman globulin (AHG) by indirect 
antiglobulin test (IAT) is recommended for determination 
of IgG reactivity.3 Titers are generally determined using a 
semiquantitative assay by serial double-fold dilution; the 
titer cutoff value is reciprocal to the highest sample dilution 
showing 1+ agglutination. Dithiothreitol (DTT) is used for 
the inactivation of IgM antibodies and, therefore, its routine 
use in immunohematology laboratories is recommended.5 
Although the column agglutination technology (CAT) has been 
described as superior in objectivity and reproducibility when 
compared with CTT because of the possible overestimation of 
the antibody titer when using CAT, it has, up to now, only been 
recommended for antibody identification and not for standard 
antibody level determination.6,7 Cho et al.8 compared the 
effectiveness of CAT and CTT for ABO antibody titration; they 
suggested that CAT-AHG could be used to standardize ABO 
antibody titration at different institutions. They measured 
only total ABO antibody, however, and did not distinguish 
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between IgM and IgG. On the other hand, a study conducted 
by Kang et al.9 investigated ABO antibody titer distribution of 
normal individuals using CTT-AHG with and without DTT 
to distinguish IgM and IgG reactivity. They performed all 
tests with CTT only, however. There are very few publications 
available in support of whether DTT can be used in CAT or 
whether DTT treatment of serum (or plasma) leads to false-
positive reactions by CAT.10 As cases of ABO-incompatible 
transplants are gradually increasing in resource-constrained 
developing countries across the globe, it has become extremely 
important for immunohematology laboratories to validate 
an accurate method to estimate precise IgM and IgG levels 
of reactivity in ABO titers in patients as well as in potential 
healthy organ or stem cell donors.
The aim of this study was to compare ABO titration results 
using six different methods available in our immunohematol-
ogy laboratory: CTT-IS, CTT-AHG with DTT, CTT-AHG 
without DTT, CAT-IS, CAT-AHG with DTT, and CAT-AHG 
without DTT. Additionally, the effectiveness of using DTT in 
ABO titration at the AHG phase was evaluated during this 
study.
Material and Methods
This observational study was conducted in the department 
of transfusion medicine at a tertiary care oncology center 
in eastern India. The study was conducted in 2018–2019 
on healthy voluntary blood donors. The selection of blood 
donors was according to the guidelines stated in the Drug and 
Cosmetic Act 194011 and the Standards for Blood Banks and 
Blood Transfusion Services.12 A total of 90 healthy individuals 
between the ages of 18 and 65 years were enrolled in this 
study. Written informed consent was obtained from each 
person before blood donation. As per the institutional policy, 
anti-A/-B titration is routinely performed on samples from 
blood donor units at our blood center; the intent was to avoid 
hemolytic reactions caused by transfusion of non–group-
specific platelet concentrates. Therefore, separate institutional 
review board approval was not obtained for this study. Thirty 
individuals, each of blood groups A, B, and O, were enrolled. 
Table 1 shows the characteristics of the enrolled individuals. 
Sample size was calculated on the basis of prevalence of the 
ABO blood groups in this part of the world as per previously 
published literature.13
Samples were taken from the diversion pouch of the 
blood collection bag for routine donor testing (e.g., ABO and 
D testing and screening for irregular RBC antibodies) as 
well as for this study. Samples for this study were collected 
into EDTA vials (BD Vacutainer; BD, Franklin Lakes, NJ) 
and stored at 2–6°C. All samples were tested for ABO/D and 
screened for irregular RBC antibodies on the fully automated 
immunohematology analyzer (VISION Analyzer for BioVue; 
Ortho Clinical Diagnostics, Pencoed, UK). All samples were 
negative for irregular RBC antibodies and were nonreactive for 
transfusion-transmitted diseases. 
The EDTA samples were centrifuged for 10 minutes at 
1400g to obtain the plasma for antibody titer determination 
by six methods: CTT-IS, CTT-AHG with DTT, CTT-AHG 
without DTT, CAT-IS, CAT-AHG with DTT, and CAT-AHG 
without DTT. Testing was performed within 24 hours of whole 
blood collection. The serial doubling dilutions were prepared, 
and the titrations were performed by two technologists. The 
results were interpreted by one physician and data collected by 
another to avoid interobserver variability. Final data analysis 
was performed independently by a statistician.
Antibody Titration Methods
CTT-is
Anti-A/-B titration using CTT-IS was performed 
according to the method described in the AABB Technical 
Manual3 and as per departmental standard operating 
procedure. Normal-ionic-strength saline was used as diluent. 
For each donor sample, 100 μL of each serial dilution of the 
donor’s plasma was pipetted into 10–12 prelabeled clean test 
tubes. One drop each of reagent RBCs (A1 and B Affirmagen; 
Ortho Clinical Diagnostics) was added to the appropriate tube. 
After incubation at ambient (22–25°C) room temperature, 
tubes were centrifuged at 1000g for 25 seconds. Agglutination 
was read macroscopically, and titer was determined as the 
reciprocal of the highest dilution showing 1+ agglutination.
CTT-ahg wiTh anD wiThouT DTT
The IAT was used to determine the anti-A/-B AHG phase 
titer. The prelabeled tubes containing serially diluted donor 
plasma and reagent RBCs were incubated at 37°C for 45 
minutes. After the incubation, the tubes were washed three 
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Table 1. Characteristics of the enrolled individuals
Blood group Samples, n Gender, male/female
Age in years, mean ± 
standard deviation
A 30 22/8 28.18 ± 6.63
B 30 24/6 29.90 ± 6.74
O 30 25/5 31.73 ± 9.54
Total 90 71/19 30.61 ± 8.48
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times using normal saline. Two drops of polyspecific AHG 
(Tulip Diagnostics, Goa, India) were added after discarding 
the last supernatant, and the tubes were finally centrifuged 
at 1000g for 15 seconds. Agglutination reactivity and titer 
endpoint were interpreted in a manner similar to that used for 
CTT-IS.
To determine the IgG antibody titer, the plasma samples 
were evaluated by IAT after pretreatment of plasma with 
an equal volume of 0.01 M DTT at 37°C for 60 minutes 
(0.01 M DTT was prepared by dissolving 0.154 g DTT 
[Himedia Laboratory, Mumbai, India] in 100 mL of pH 
7.3 phosphate-buffered saline). Testing followed the same 
procedure as that used for the CTT-AHG without DTT, and 
results were interpreted after adjusting the dilution factor due 
to DTT pretreatment of plasma.
CaT-is
Anti-A/-B titration using the CAT-IS was performed 
in reverse diluent cards (MTS Reverse Group Diluent Card; 
Ortho Clinical Diagnostics) that were labeled separately for 
anti-A and anti-B. The CAT used bead-column agglutination. 
Diluted serum (40 μL) and 10 μL of A1 and B reagent RBCs 
were dispensed into separate microcolumns and centrifuged 
for 5 minutes in a dedicated centrifuge for CAT (MTS, BioVue 
System; Ortho Clinical Diagnostics). The cutoff value for the 
agglutination grading using CAT-IS was set to 1+, similar to 
that used for CTT, and interpretation was determined in the 
same manner.
CaT-ahg wiTh anD wiThouT DTT
Anti-A/-B titration using CAT was performed in 
polyspecific AHG cards (MTS AHG Card; Ortho Clinical 
Diagnostics) that were labeled separately for anti-A and anti-B. 
Diluted serum (40 μL), 10 μL of A1 and B reagent RBCs, and 
50 μL of low-ionic-strength solution were dispensed into 
separate microcolumns, followed by 15-minute incubation at 
37°C and 5-minute centrifugation in a dedicated centrifuge 
for CAT (MTS, BioVue System; Ortho Clinical Diagnostics). 
The titer endpoint was the reciprocal of the highest dilution 
yielding 1+ agglutination. 
Plasma samples were also evaluated by CAT using anti-
IgG cards (MTS IgG Card; Ortho Clinical Diagnostics) after 
pretreatment of plasma with DTT. (Pre-study validation of 
DTT on the CAT was performed by using plasma containing 
known amounts of IgG and IgM antibodies as positive 
control.) An additional control was run in parallel using 
plasma containing IgG only along with the reagent RBCs 
(Affirmagen A1 and B RBCs; Ortho Clinical Diagnostics) in 
the presence of DTT to exclude any DTT interference with the 
test method. Plasma pretreatment with DTT and testing of 
the serial dilutions were performed as described under CTT-
AHG with DTT. The results were interpreted in microcolumns 
after adjusting the dilution factor due to DTT pretreatment of 
plasma.
Statistical Analysis
The distributions of antibody titers according to age-
group and gender were evaluated and compared by analysis 
of variance and the two-sample t test, respectively. The 
consistency between the antibody titer measured by the CTT 
and CAT was evaluated using kappa analysis. Furthermore, 
the correlation between the CTT and CAT was evaluated 
by calculating the Pearson correlation coefficient through 
linear regression analysis. Data were primarily collected 
and analyzed using a statistics software (Excel; Microsoft, 
Redmond, WA). Further statistical calculation was performed 
(R software, version 3.4.2; The R Project for Statistical 
Computing, Vienna, Austria), and p values <0.05 were 
considered statistically significant.
Results
The distribution of anti-A/-B titers according to age-group 
is shown in Table 2. There were no statistically significant 
differences among age-groups. Table 3 shows ABO titer 
distribution according to gender; no statistical differences 
were observed between male and female individuals. The 
distribution of ABO titers according to titration methods is 
shown in Table 4. The median values of anti-A/-B titers by 
IS were found higher than those found by AHG in both CTT 
and CAT among group B and A individuals (p < 0.05 for all 
methods), whereas no statistically significant differences 
were observed in group O individuals between IS and AHG 
anti-A/-B titers, estimated by each method. A moderate 
agreement was observed between CTT-IS and CAT-IS (kappa 
value of 0.46), as shown in Table 5. Moreover, Table 5 shows 
poor agreement between the CTT-AHG and CAT-AHG titers 
with and without DTT pretreatment (kappa value of 0.11 
and 0.20, respectively). A positive correlation was observed 
between the anti-A/-B titer results obtained using the CTT 
and CAT (p < 0.01 for each method) among all individuals 
(Table 6). Median anti-A/-B AHG titers were reduced after 
DTT treatment in samples from all blood groups, regardless of 
method, as shown in Table 4. Figure 1 compares the differences 
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Table 2. Distribution of ABO antibody titers according to age–range groups
ABO antibody Samples, n
Age range,  
years










Anti-A in blood group B 16 18–29 32 (16–32) 2 (0–4) 16 (8–64) 16 (8–16) 0 (0) 4 (4–16)
11 30–39 32 (16–96) 4 (2–10) 32 (12–96) 16 (12–32) 0 (0–1) 8 (4–16)
1 40–49 32 0 8 16 0 2
2* 50–65 32 (32) 2 (1–2) 18 (4–32) 12 (8–16) 0 (0) 6 (4–8)
Total 30
Anti-B in blood group A 17 18–29 32 (16–64) 4 (1–8) 64 (8–64) 32 (8–64) 1 (0–2) 16 (7–32)
8 30–39 16 (4–28) 4 (1–8) 16 (7–32) 8 (4–40) 0 (0–1) 30 (4–28)
3* 40–49 64 (16–64) 2 (2) 32 (16–32) 64 (16–64) 0 (0–8) 32 (0–32)
2* 50–65 16 (16) 2 (0–4) 12 (8–16) 10 (4–16) 0.5 (0–1) 8 (8)
Total 30
Anti-A in blood group O 15 18–29 256 (96–256) 128 (48–256) 256 (128–384) 64 (32–64) 8 (1–16) 32 (16–64)
10 30–39 192 (80–256) 32 (32–64) 256 (128–448) 48 (20–64) 4 (1–8) 48 (20–112)
3* 40–49 256 (32–256) 64 (32–64) 128 (64–128) 16 (16–32) 8 (2–16) 16 (16–32)
2* 50–65 80 (32–128) 96 (64–128) 136 (16–256) 12 (8–16) 24 (16–32) 16 (0–32)
Total 30
Anti-B in blood group O 15 18–29 128 (128–512) 128 (48–192) 128 (128–512) 64 (48–128) 4 (2–12) 32 (16–48)
10 30–39 288 (37–512) 96 (40–128) 512 (160–512) 32 (32–64) 6 (1–16) 32 (20–64)
3* 40–49 256 (16–512) 64 (2–64) 128 (128–256) 32 (8–32) 4 (0–16) 32 (16–32)
2* 50–65 128 (128) 192 (128–256) 144 (32–256) 24 (16–32) 48 (32–64) 66 (4–128)
Total 30
*Upper and lower ranges of titers reported instead of interquartile range.
CAT = column agglutination technology; IS = immediate spin; AHG = antihuman globulin; DTT = dithiothreitol; CTT = conventional tube test. 
Table 3. Distribution of ABO antibody titers according to gender
ABO antibody Samples, n Gender










Anti-A in blood group B 24 Male 32 (16–64) 2 (0–4) 16 (8–64) 16 (8–16) 0 (0–1) 8 (4–16)
6 Female 32 (32) 2 (2) 24 (16–32) 16 (16–28) 0 (0) 4 (4)
Total 30
Anti-B in blood group A 22 Male 16 (16–64) 4 (1–8) 16 (10–64) 16 (8–32) 1 (0–2) 12 (5–28)
8 Female 48 (16–80) 5 (2–8) 48 (8–80) 64 (8–128) 1 (0–2) 32 (7–40)
Total 30
Anti-A in blood group O 25 Male 256 (64–256) 64 (32–128) 256 (128–256) 32 (16–64) 4 (1–8) 32 (16–64)
5 Female 256 (128–256) 256 (256) 128 (64–512) 64 (32–64) 16 (16–32) 64 (32–64)
Total 30
Anti-B in blood group O 25 Male 256 (64–512) 128 (32–128) 256 (128–512) 32 (32–64) 4 (1–16) 32 (16–64)
5 Female 128 (128) 128 (64–128) 64 (32–128) 64 (32–64) 16 (4–32) 16 (16–32)
Total 30
CAT = column agglutination technology; IS = immediate spin; AHG = antihuman globulin; DTT = dithiothreitol; CTT = conventional tube test.
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in the antibody titer results between CTT-AHG and CAT-AHG 
with and without DTT treatment.
Discussion
Significant differences in the interpretability of anti-A/-B 
titers were observed among different testing methods in 
this study. Until now, no standard serologic method for 
ABO antibody titration has been established in most of the 
immunohematology laboratories across the Asia-Pacific 
region.14,15 The ABO antibody detection capability for each 
detection method varies significantly; therefore, knowing 
the differences between titer distributions exhibited by 
each method and each institution could be important. The 
advantage of CAT is that it may reduce the interobserver 
and interinstitutional variation, and analysis time could be 
shortened, as demonstrated by Shirey et al.16 In this study, 
we performed ABO titrations by six different methods. The 
median values of ABO antibodies by CTT and CAT in our 
study were similar to those of Park et al.,17 but the interquartile 
ranges were narrower than theirs, which could be due to 
differences in sample size between the two studies.
We found that the median values of anti-A/-B titers by IS 
were higher than those by AHG both in CTT and CAT in group 
B and A individuals, whereas almost similar IS and AHG titer 
results were observed in group O individuals. This finding 
is similar to that from the study conducted by Kang et al.,18 
where flow cytometry was used as a gold-standard test 
method. This observation might be because IgM anti-A/-B 
is the predominant isotype found in group B and group A 
Table 4. Distribution of ABO antibody titers according to titration method
ABO antibody Samples, n










Anti-A in blood group B 30 32 (16–32) 2 (0–4) 16 (8–64) 16 (8–16) 0 (0) 6 (4–16)
Anti-B in blood group A 30 24 (16–64) 4 (1–8) 24 (8–64) 24 (8–64) 1 (0–2) 16 (5–32)
Anti-A in blood group O 30 256 (64–256) 64 (32–128) 192 (128–256) 32 (16–64) 8 (1–16) 32 (16–64)
Anti-B in blood group O 30 128 (64–512) 128 (40–128) 256 (128–512) 48 (32–64) 6 (2–16) 32 (16–64)
CAT = column agglutination technology; IS = immediate spin; AHG = antihuman globulin; DTT = dithiothreitol; CTT = conventional tube test.
Table 5. Consistency between ABO antibody titer results obtained 
using CTT and CAT with and without DTT treatment
Method
Concordance  
rate (%) Cohen’s kappa
CTT-IS vs. CAT-IS 0.72 0.46
CTT-AHG vs. CAT-AHG 
(with DTT)
0.48 0.11
CTT-AHG vs. CAT-AHG 
(without DTT)
0.52 0.20
CTT = conventional tube test; CAT = column agglutination technology; 
DTT = dithiothreitol; IS = immediate spin; AHG = antihuman globulin.
Table 6. Correlation between ABO antibody titer results obtained 




CTT-IS vs. CAT-IS 0.70 <0.01
CTT-AHG vs. CAT-AHG 
(with DTT)
0.98 <0.01
CTT-AHG vs. CAT-AHG 
(without DTT)
0.92 <0.01
CTT = conventional tube test; CAT = column agglutination technology; 
DTT = dithiothreitol; IS = immediate spin; AHG = antihuman globulin.
Fig. 1 Differences of ABO-antibody antihuman globulin (AHG) titers 
between conventional tube test (CTT) and column agglutination 
technology (CAT) with and without dithiothreitol (DTT) treatment. 
The box plot shows AHG antibody titer differences between samples 
treated or not treated with DTT. In the box plot, the central rectangle 
spans the first quartile to the third quartile. A segment inside the 
rectangle shows the median, and whiskers above and below the box 
show the locations of the minimum and maximum values. The figure 
reveals that the median difference is greater in the DTT-treated 
group than in the group without DTT treatment (CTT vs. CAT).
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individuals, whereas IgG ABO is present in a significant 
amount in group O individuals.3 In addition to that, group O 
individuals also produce anti-A,B.3 The fact that anti-A,B does 
not contain separable anti-A and anti-B components might 
cause some interference in the anti-A/-B titer results in group 
O individuals.
Moderate agreement was observed between CTT-IS and 
CAT-IS, but agreement was poor between CTT-AHG and 
CAT-AHG titers with and without DTT pretreatment in this 
study; this finding is quite similar to results published by 
Nayak et al.19 The high value of anti-A/-B titers observed in 
CAT in our study could be due to microcolumns using glass 
beads as the column component or the presence of 3 percent 
polyethylene glycol in reverse diluent cassettes. The study by 
Tanabe20 also reported a similar observation when various 
CAT methods were compared; the study suggested that the 
bead-column agglutination method shows high maximum 
titer compared with other gel-column agglutination methods 
because the serum-to-cell ratio is slightly higher in CAT 
using glass beads. Because serum-to-cell ratios suggested 
by manufacturers’ instructions are different depending on 
the column component, it is recommended to distinguish 
between the two CAT methods when comparing target levels 
of ABO antibody titer. A positive correlation that was observed 
in this study between the anti-A/-B titer results obtained 
using the CTT and CAT is in agreement with other published 
literatures.10,19 Antibody titration with DTT-treated plasma can 
reduce the impact of IgM anti-A/-B on the measurement of IgG 
ABO by breaking the disulfide bonds that hold the structure of 
the IgM pentameric molecule. Moreover, the polyspecific AHG 
used in the CAT could cross-react with IgA and IgM, as well 
as with the complement components, which could potentially 
cause false elevation in AHG titer measurements by the IAT 
method due to carry-over of reactivity of IgM anti-A/-B at 
37°C.
In our study, we compared the antibody titer obtained 
using DTT-treated or untreated plasma samples and found 
that the median value of anti-A/-B AHG titers was reduced 
by DTT treatment in samples from all blood groups tested 
in each method. The differences of AHG titer results were 
compared between CAT and CTT, and the median difference 
was found slightly higher in DTT-treated samples than in 
DTT-untreated samples. No evidence of falsely elevated titers 
due to DTT treatment of the plasma samples was observed 
using CAT, excluding the possibilities of positive bias by DTT 
pretreatment during CAT. Our observations strongly suggest 
that DTT treatment is needed to measure the exact IgG 
anti-A/-B titers, and, therefore, DTT-treated plasma should be 
tested with anti-IgG in the AHG phase to obtain the precise 
IgG titers of ABO antibodies.
The wide variability of the titer results among laboratories 
as well as among the different methods that are commonly 
being used for ABO antibody titration is a matter of great 
concern, especially for ABO-incompatible transplantations.21,22 
If the results for the antibody titer are found falsely elevated 
by a new method, then treatment such as plasma exchange 
that is not necessary for a specific patient might be considered 
inadvertently, which could ultimately increase the cost of the 
treatment. On the contrary, if the titration results are found 
lower than those with the conventional method, patients 
may be deprived of receiving a potential treatment. As most 
transplant physicians remain focused only on the target 
titer without taking into account the differences that may 
arise in these values due to the choice of the method used, 
we recommend that they must be cautious in interpreting 
the results of ABO titer, and laboratories should provide 
appropriate information on the method of testing to facilitate 
accurate interpretation of results.
There are some limitations in our study, including a 
relatively small sample population. Comparison with flow 
cytometry, which is a gold-standard test for titer estimation, 
could not be carried out because of the higher cost of the 
method; this lack of testing could be considered another 
limitation. Moreover, the variation between CAT and CTT 
could be reduced if we use titer endpoints of 1+ in CAT and 
w+ in CTT as suggested by AuBuchon et al.23 In our study, we 
compared CTT with CAT, which uses a glass-bead column, 
but there are other CAT formulations available that use gel 
columns, which may give different results.
To reduce the variation of titration results between and 
within different methods, an ABO titration external quality 
assurance (EQA) program is urgently needed for most of 
the laboratories in the Asia-Pacific region. Development of a 
standard method and participation in an EQA program should, 
over time, reduce variation and enable transferrable results 
across testing centers, which will assist in consistent clinical 
interpretation.14 New advancements like clinical application of 
kodecytes may be considered in contrast to natural cells for 
ABO titrations. The level of ABO antigen on kodecytes can be 
precisely controlled, and it has the potential to be standardized 
globally, thus resulting in more accurate clinical interpretation 
of ABO titer results.24 In addition, the application of kodecytes 
for ABO titration in EQA programs needs to be explored in the 
future.
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Recently, it was demonstrated that A and B subtype 
antigens are expressed differentially between erythrocytes 
and organs; for example, only subtype II A/B antigens are 
expressed on cardiac endothelium; thus, only antibodies 
against A or B subtype II antigens should be considered 
donor specific in the setting of ABO-incompatible cardiac 
transplantation.25 Erythrocyte agglutination methods (CTT/
CAT) provide limited information on antibody isotype 
determination, since they do not differentiate ABO subtypes. 
Therefore, new methods are developing in the form of ABH-
glycan microarray or Luminex bead based–solid-phase, which 
will be used in the near future for accurate determination 
of donor-specific ABO subtypes in the setting of ABO-
incompatible organ transplantation.26,27
Finally, we conclude that a uniform approach of selecting 
the method for ABO titration is highly necessary, and it is 
strongly recommended that caution be exercised in interpret-
ing the ABO titer, taking the method used into consideration, 
particularly during selection of treatment protocol for ABO 
antibody neutralization.
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